Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 125,230,504
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.60
  • Price/Sales 7.77
  • Price/Cash Flow 20.86
  • Price/Book 17.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.17 +8.72%
on 09/05/17
49.26 -0.30%
on 09/20/17
+3.93 (+8.70%)
since 08/18/17
3-Month
41.03 +19.69%
on 07/27/17
49.26 -0.30%
on 09/20/17
+5.94 (+13.76%)
since 06/20/17
52-Week
30.89 +58.98%
on 11/23/16
49.26 -0.30%
on 09/20/17
+2.88 (+6.23%)
since 09/20/16

Most Recent Stories

More News
Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View

Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.

BAYRY : 32.9100 (-0.72%)
NVO : 49.11 (+0.95%)
NVS : 85.78 (-0.08%)
PFE : 35.99 (+1.52%)
The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

TROW : 85.72 (+0.73%)
AAPL : 156.07 (-1.68%)
NVO : 49.11 (+0.95%)
CCL : 64.48 (-1.13%)
PFE : 35.99 (+1.52%)
Top Analyst Reports for Apple, Pfizer & Carnival

Top Analyst Reports for Apple, Pfizer & Carnival

TROW : 85.72 (+0.73%)
APA : 43.05 (+3.11%)
AAPL : 156.07 (-1.68%)
NVO : 49.11 (+0.95%)
CCL : 64.48 (-1.13%)
PFE : 35.99 (+1.52%)
Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?

Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).

MYL : 31.39 (+1.32%)
NVO : 49.11 (+0.95%)
MNTA : 16.80 (+0.90%)
TEVA : 17.11 (-0.47%)
Novo Nordisk and Discovery Education Launch "Super Health, Super You" National Community Health Challenge and Learning Curriculum

Novo Nordisk, a global health care company and Discovery Education, the leading provider of digital content and professional development for K-12 classrooms, are challenging elementary school students...

DISCK : 20.07 (+0.05%)
NVO : 49.11 (+0.95%)
DISCA : 21.26 (-0.14%)
DISCB : 22.00 (-7.37%)
Novo Nordisk's Tresiba Gets Canadian Nod

Novo Nordisk's (NVO) Tresiba is approved by Health Canada for the once-daily treatment of adults with diabetes mellitus to improve glycemic control.

NVO : 49.11 (+0.95%)
REGN : 438.17 (+1.57%)
ADRO : 11.00 (unch)
ALXN : 142.92 (+0.06%)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award

The Society for Clinical Research Sites (SCRS) today announced the finalists for the 2017 SCRS Eagle Award(TM). The finalists were selected from companies nominated by SCRS members. Qualifying nominees...

NVO : 49.11 (+0.95%)
MRK : 65.79 (-0.24%)
LLY : 82.02 (+0.35%)
GSK : 40.18 (+0.65%)
Corporate News Blog - Novo Nordisk's Victoza(R) Receives Approval from FDA

Research Desk Line-up: SciClone Pharma Post Earnings Coverage

SCLN : 11.10 (unch)
NVO : 49.11 (+0.95%)
Novo Nordisk reports on share repurchase programme

Global healthcare company Novo Nordisk A/S (CPH:NOVOB) announced on Monday that under its share repurchase programme, it has accumulated a total of 35,032,971 B shares equal to a transaction value of DKK9,186,835,148....

NVO : 49.11 (+0.95%)
Novo Nordisk reports on share repurchase programme

Global healthcare company Novo Nordisk A/S (CPH:NOVOB) announced on Monday that under its share repurchase programme, it has accumulated a total of 35,032,971 B shares equal to a transaction value of DKK9,186,835,148....

NVO : 49.11 (+0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 49.58
1st Resistance Point 49.34
Last Price 49.11
1st Support Level 48.79
2nd Support Level 48.48

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.